SOLENO THERAPEUTICS INC (SLNO) FY2025 10-K Annual Report
SOLENO THERAPEUTICS INC (SLNO) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 25, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
SOLENO THERAPEUTICS INC FY2025 10-K Analysis
Business Overview
- • Core business model: Biopharmaceutical company developing and commercializing novel therapeutics for rare diseases, with initial focus on Prader-Willi syndrome (PWS)
- • New product: FDA approval and first commercial sales of VYKAT XR (diazoxide choline extended-release tablets) for hyperphagia in PWS patients aged 4 and older in March 2025
- • Strategic shift: Transition from clinical development to commercialization phase with a 65-person U.S. field force targeting PWS specialists and multidisciplinary care teams
- • Quantitative metric: Identified PWS patient population approx. 10,000 in U.S. with growing diagnosis rates; product priced at $6.0976 per mg with global patent protection expiring 2026-2035
- • Noteworthy fact: In February 2026, new U.S. legislation codified FDA’s interpretation allowing multiple orphan drug approvals for different subpopulations within the same rare disease, impacting market exclusivity and competition strategy
Management Discussion & Analysis
- • No revenue or YoY change figures disclosed
- • No profitability or operating margin data provided
- • No segment performance data included
- • No cash flow, buybacks, dividends, or capex amounts stated
- • Forward-looking statements highlight risks including maintaining profitability, capital needs, intellectual property, regulatory approvals, and market competition
Risk Factors
- • Regulatory risk: FDA approval of VYKAT XR in March 2025 triggered contingent payments of $7.0 million due Q1 2026
- • Macroeconomic exposure: $50 million outstanding loan with Oxford at 1-month SOFR + 5.50% interest, with $100 million more contingent on mutual consent
- • Operational risk: Manufacturing and supply chain costs included in $40.6 million R&D spend, reduced by $7.5 million from prior year NDA support
- • Competitive risk: Commercial launch costs increased by $23.4 million for marketing and commercial programs supporting VYKAT XR sales
- • Financial risk: Contingent liability for milestone payments up to $21.2 million linked to VYKAT XR sales milestones of $100 million and $200 million
SOLENO THERAPEUTICS INC FY2025 Key Financial MetricsXBRL
Revenue
$190M
Net Income
$21M
▲ +111.9% YoY
Operating Margin
4.9%
Net Margin
11.0%
ROE
4.6%
▲ +7638bp YoY
Total Assets
$564M
▲ +70.4% YoY
EPS (Diluted)
$0.39
▲ +108.9% YoY
Operating Cash Flow
$47M
▲ +167.7% YoY
Source: XBRL data from SOLENO THERAPEUTICS INC FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on SOLENO THERAPEUTICS INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.